Re: NIPT Stream Log - "Mark Brewer summarises his initiation...

"Mark Brewer summarises his initiation report on Premaitha, a molecular diagnostics company that has developed and launched a non-invasive prenatal test (NIPT), targeted initially at ex-US markets. He explains how the company is primarily products-based, addressing the needs of its laboratory customers, and how it is differentiated from other NIPTs by a faster turnaround time, a reduced need to re-run tests (failure rate), the fact that the test is CE marked and that it matches the specifications of National screening programmes. He believes Premaitha is well placed to capitalise on an addressable market worth $7.5-20.0bn. First-year revenues of c£2.5m are indicative of early traction in a European market that is underpenetrated compared with the US (c1.4% vs 25%)." Note from finnCap on Research Tree